LAB Quote, Financials, Valuation and Earnings

Ainos has a net margin of -59.9% compared to Standard BioTools's net margin of -15991.17%. Standard BioTools's return on equity of -48.03% beat Ainos's return on equity of -52.95%.

Standard BioTools has a consensus price target of --, signalling upside risk potential of 68.49%. On the other hand Ainos has an analysts' consensus of -- which suggests that it could fall by --. Given that Standard BioTools has higher upside potential than Ainos, analysts believe Standard BioTools is more attractive than Ainos.

Standard BioTools has a beta of 1.606, which suggesting that the stock is 60.617% more volatile than S&P 500. In comparison Ainos has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.704%.

Standard BioTools has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ainos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools pays -- of its earnings as a dividend. Ainos pays out -- of its earnings as a dividend.

Standard BioTools quarterly revenues are $45M, which are larger than Ainos quarterly revenues of $20.7K. Standard BioTools's net income of -$26.9M is lower than Ainos's net income of -$3.7M. Notably, Standard BioTools's price-to-earnings ratio is -- while Ainos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools is 3.28x versus 34.77x for Ainos. Usually stocks with elevated PS ratios are considered overvalued.

Intelligent Bio Solutions has a net margin of -59.9% compared to Standard BioTools's net margin of -307.88%. Standard BioTools's return on equity of -48.03% beat Intelligent Bio Solutions's return on equity of -176.44%.

Standard BioTools has a consensus price target of --, signalling upside risk potential of 68.49%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 782.35%. Given that Intelligent Bio Solutions has higher upside potential than Standard BioTools, analysts believe Intelligent Bio Solutions is more attractive than Standard BioTools.

Standard BioTools has a beta of 1.606, which suggesting that the stock is 60.617% more volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Standard BioTools has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

Standard BioTools quarterly revenues are $45M, which are larger than Intelligent Bio Solutions quarterly revenues of $872.3K. Standard BioTools's net income of -$26.9M is lower than Intelligent Bio Solutions's net income of -$2.7M. Notably, Standard BioTools's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools is 3.28x versus 0.63x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of -59.9% compared to Standard BioTools's net margin of -11.09%. Standard BioTools's return on equity of -48.03% beat LENSAR's return on equity of -56.16%.

Standard BioTools has a consensus price target of --, signalling upside risk potential of 68.49%. On the other hand LENSAR has an analysts' consensus of -- which suggests that it could grow by 26.58%. Given that Standard BioTools has higher upside potential than LENSAR, analysts believe Standard BioTools is more attractive than LENSAR.

Standard BioTools has a beta of 1.606, which suggesting that the stock is 60.617% more volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Standard BioTools has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

Standard BioTools quarterly revenues are $45M, which are larger than LENSAR quarterly revenues of $13.5M. Standard BioTools's net income of -$26.9M is lower than LENSAR's net income of -$1.5M. Notably, Standard BioTools's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools is 3.28x versus 2.03x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.

Zomedica has a net margin of -59.9% compared to Standard BioTools's net margin of -95.71%. Standard BioTools's return on equity of -48.03% beat Zomedica's return on equity of -27.17%.

Standard BioTools has a consensus price target of --, signalling upside risk potential of 68.49%. On the other hand Zomedica has an analysts' consensus of -- which suggests that it could grow by 108.33%. Given that Zomedica has higher upside potential than Standard BioTools, analysts believe Zomedica is more attractive than Standard BioTools.

Standard BioTools has a beta of 1.606, which suggesting that the stock is 60.617% more volatile than S&P 500. In comparison Zomedica has a beta of 1.044, suggesting its more volatile than the S&P 500 by 4.385%.

Standard BioTools has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zomedica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools pays -- of its earnings as a dividend. Zomedica pays out -- of its earnings as a dividend.

Standard BioTools quarterly revenues are $45M, which are larger than Zomedica quarterly revenues of $7M. Standard BioTools's net income of -$26.9M is lower than Zomedica's net income of -$6.7M. Notably, Standard BioTools's price-to-earnings ratio is -- while Zomedica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools is 3.28x versus 4.40x for Zomedica. Usually stocks with elevated PS ratios are considered overvalued.